VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

NGM Biopharmaceuticals Executive Compensation (FY22)

NGM · Executive and director compensation, fiscal 2022 only
Chief executive, fiscal 2022
◇
David Woodhouse
Latest say-on-pay support
=
May 10, 2023
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The NGM Biopharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of October 13, 2026Latest filing (8-K): May 12, 2023
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
NGM Biopharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
121 figures on this page: 119 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.
Who is NGM Biopharmaceuticals' chief executive and what were they paid?
Total compensation for David Woodhouse, Chief Executive Officer, came to $5,933,500 in fiscal 2022.
What was NGM Biopharmaceuticals' say-on-pay result?
Shareholders recorded 97.7% support for the say-on-pay proposal at the meeting held May 10, 2023 for fiscal 2022.
Which companies are in NGM Biopharmaceuticals' peer group?
The disclosed peer group includes Alector, Inc., Allakos Inc., Allogene Therapeutics, Inc., AnaptysBio, Inc. and Apellis Pharmaceuticals, Inc., among others.
What is NGM Biopharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2022 is 24:1, against median employee compensation of $251,078.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Woodhouse
Chief Executive Officer
◇——◇◇—◇◇
Siobhan Nolan Mangini
President and Chief Financial Officer
◇——◇◇—◇◇
Hsiao Lieu
Executive Vice President and Chief Medical Officer
◇◇—◇◇—◇◇
Jin-Long Chen
Founder and Chief Scientific Officer
◇——◇◇—◇◇
Valerie Pierce
Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
◇◇—◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David J. WoodhouseOPTION◇——◇—◇◇
Hsiao D. LieuOPTION◇——◇—◇◇
Hsiao D. LieuOPTION◇——◇—◇◇
Jin-Long ChenOPTION◇——◇—◇◇
Siobhan Nolan ManginiOPTION◇——◇—◇◇
Siobhan Nolan ManginiOPTION◇——◇—◇◇
Valerie PierceOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
David WoodhouseOption◇—◇3/2/2032
Option◇—◇3/16/2031
Siobhan Nolan ManginiOption◇—◇3/2/2032
Option◇—◇6/30/2032
Option◇—◇3/16/2031
Hsiao LieuOption◇—◇11/3/2032
Option◇—◇3/2/2032
Option◇—◇3/16/2031
Jin-Long ChenOption◇—◇3/2/2032
Option◇—◇3/16/2031
Valerie PierceOption◇—◇3/2/2032
Option◇—◇3/16/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2022
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William J. Rieflin
Board chair
◇————◇◇
Shelly D. Guyer
◇—◇———◇
David V. Goeddel, Ph.D
Lead independent director
◇—◇———◇
Suzanne Sawochka Hooper
◇—◇———◇
Carole Ho, M.D
◇—◇———◇
Roger M. Perlmutter, M.D., Ph.D
◇—◇———◇
Mark Leschly
◇—————◇
David J. Woodhouse, Ph.D and Jin-Long Chen, Ph.D served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
  • Alector, Inc. ALEC
  • Allakos Inc. ALLK
  • Allogene Therapeutics, Inc. ALLO
  • AnaptysBio, Inc. ANAB
  • Apellis Pharmaceuticals, Inc. APLS
  • Arcturus Therapeutics Holdings, Inc. ARCT
  • Arcus Biosciences, Inc. RCUS
  • Atara Biotherapeutics, Inc. ATRA
  • Cytokinetics, Incorporated CYTK
  • CytomX Therapeutics, Inc. CTMX
  • Denali Therapeutics Inc. DNLI
  • Dicerna Pharmaceuticals, Inc. AGIO
  • Editas Medicine, Inc. EDIT
  • Forma Therapeutics Holdings, Inc. MRSN
  • Gossamer Bio, Inc. GOSS
  • Kodiak Sciences Inc. KOD
  • Madrigal Pharmaceuticals, Inc. MDGL
  • Replimune Group, Inc. REPL
  • Rubius Therapeutics, Inc. symbol not shown
  • Scholar Rock Holding Corporation SRRK
  • Turning Point Therapeutics, Inc. RLAY

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2022May 10, 2023=◇◇◇
2021May 18, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- David Woodhouse (Chief Executive Officer), FY2022 total compensation $5,933,500 (base salary $610,000) [exec_comp, SEC accession 0001628280-23-009712, filed 2023-03-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when NGM Biopharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact NGM Biopharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where NGM Biopharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether NGM Biopharmaceuticals' disclosed peer group is defensible, who names NGM Biopharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
121 figures on this page: 119 cited to the filing that reported them, 2 calculated from figures it prints.
119 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-23-143465
  2. 0001628280-23-009712
    CEO PAY RATIO · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Summary Compensation Table
  3. 0001193125-22-158629
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “NGM Biopharmaceuticals executive compensation, FY2022.” https://intel.velarion.ai/comp/NGM (accessed 2026).
Short form: data: Velarion

The NGM Biopharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about NGM Biopharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers NGM Biopharmaceuticals discloses

The companies named in NGM's own disclosed peer group.

Alector, Inc.Allakos Inc.Allogene Therapeutics, Inc.AnaptysBio, Inc.Apellis Pharmaceuticals, Inc.Arcturus Therapeutics Holdings, Inc.Arcus Biosciences, Inc.Atara Biotherapeutics, Inc.Cytokinetics, IncorporatedCytomX Therapeutics, Inc.Denali Therapeutics Inc.Dicerna Pharmaceuticals, Inc.Editas Medicine, Inc.Forma Therapeutics Holdings, Inc.Gossamer Bio, Inc.Kodiak Sciences Inc.Madrigal Pharmaceuticals, Inc.Replimune Group, Inc.Scholar Rock Holding CorporationTurning Point Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy